Scholarlink

<p>Cutaneous melanoma (CM), with a continuously rising incidence worldwide, represents the most aggressive type of skin cancer, and it leads to the majority of skin cancer-related deaths. Approximately 50% of CM carry the activating BRAF<sup>V600</sup> mutation and, although BRAF inhibitors have demonstrated clinical efficacy, most patients often develop early resistance to treatment. Aberrant expression of non-coding RNAs (ncRNAs), which represent less than 2% of the entire transcriptome, has been implicated in CM development and progression. By using BRAF<sup>V600</sup>-mutant CM <i>in vitro</i> and <i>in vivo</i> models, we have recently demonstrated that the loss of Spry1 expression impairs BRAF<sup>V600</sup>-mutant CM progression. Therefore, the extensive long and small ncRNA datasets generated in this study might represent a valuable resource for the characterization of their roles in BRAF<sup>V600</sup>-mutant CM initiation and progression upon Spry1 loss, thus providing a comprehensive resource to support future studies on BRAF<sup>V600</sup>-mutant CM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-coding RNA profiling in BRAFV600E-mutant cutaneous melanoma before and after Spry1 depletion

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月2日

查看全文
  • Jessica Lamberti,
  • Domenico Memoli,
  • Barbara Montico,
  • Francesco Silvestro,
  • Roberto Guerrieri,
  • Francesca Colizzi,
  • Alessandro Weisz,
  • Annamaria Salvati,
  • Elisabetta Fratta,
  • Giovanni Nassa

摘要

Cutaneous melanoma (CM), with a continuously rising incidence worldwide, represents the most aggressive type of skin cancer, and it leads to the majority of skin cancer-related deaths. Approximately 50% of CM carry the activating BRAFV600 mutation and, although BRAF inhibitors have demonstrated clinical efficacy, most patients often develop early resistance to treatment. Aberrant expression of non-coding RNAs (ncRNAs), which represent less than 2% of the entire transcriptome, has been implicated in CM development and progression. By using BRAFV600-mutant CM in vitro and in vivo models, we have recently demonstrated that the loss of Spry1 expression impairs BRAFV600-mutant CM progression. Therefore, the extensive long and small ncRNA datasets generated in this study might represent a valuable resource for the characterization of their roles in BRAFV600-mutant CM initiation and progression upon Spry1 loss, thus providing a comprehensive resource to support future studies on BRAFV600-mutant CM.